Alvotech (ALVO) Competitors $8.63 -0.10 (-1.15%) Closing price 04:00 PM EasternExtended Trading$8.84 +0.21 (+2.42%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVO vs. VTRS, QGEN, ASND, BBIO, BPMC, VRNA, ROIV, ELAN, RVMD, and LEGNShould you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Alvotech vs. Its Competitors Viatris Qiagen Ascendis Pharma A/S BridgeBio Pharma Blueprint Medicines Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Viatris (NASDAQ:VTRS) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation. Which has more risk and volatility, VTRS or ALVO? Viatris has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Which has preferable earnings & valuation, VTRS or ALVO? Alvotech has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.74B0.71-$634.20M-$3.17-2.80Alvotech$491.98M5.29-$231.86M$0.3723.32 Is VTRS or ALVO more profitable? Alvotech has a net margin of 16.42% compared to Viatris' net margin of -26.45%. Viatris' return on equity of 16.20% beat Alvotech's return on equity.Company Net Margins Return on Equity Return on Assets Viatris-26.45% 16.20% 7.01% Alvotech 16.42%-36.37%12.70% Do analysts recommend VTRS or ALVO? Viatris presently has a consensus target price of $10.40, indicating a potential upside of 17.12%. Alvotech has a consensus target price of $16.00, indicating a potential upside of 85.40%. Given Alvotech's stronger consensus rating and higher possible upside, analysts plainly believe Alvotech is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80Alvotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer VTRS or ALVO? In the previous week, Viatris had 10 more articles in the media than Alvotech. MarketBeat recorded 15 mentions for Viatris and 5 mentions for Alvotech. Viatris' average media sentiment score of 1.20 beat Alvotech's score of 0.65 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in VTRS or ALVO? 79.9% of Viatris shares are owned by institutional investors. 0.1% of Viatris shares are owned by insiders. Comparatively, 0.5% of Alvotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryAlvotech beats Viatris on 10 of the 16 factors compared between the two stocks. Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALVO vs. The Competition Export to ExcelMetricAlvotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.63B$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E Ratio15.058.2821.0120.09Price / Sales5.29303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book-6.307.678.125.65Net Income-$231.86M-$55.28M$3.25B$257.91M7 Day Performance1.29%2.50%0.97%2.09%1 Month Performance-4.22%11.70%7.36%11.13%1 Year Performance-27.54%4.89%31.31%18.40% Alvotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALVOAlvotech2.7275 of 5 stars$8.63-1.1%$16.00+85.4%-27.1%$2.63B$491.98M15.051,032Analyst ForecastVTRSViatris3.2683 of 5 stars$9.20-1.3%$10.40+13.0%-21.7%$10.94B$14.74B-2.9032,000Trending NewsQGENQiagen3.7474 of 5 stars$47.49-1.8%$49.40+4.0%+16.9%$10.75B$1.98B119.075,765Positive NewsASNDAscendis Pharma A/S3.6333 of 5 stars$175.98+1.0%$220.67+25.4%+27.9%$10.65B$393.54M-28.021,017Positive NewsBBIOBridgeBio Pharma4.6238 of 5 stars$43.50-1.1%$58.85+35.3%+67.0%$8.35B$221.90M-12.32400Analyst RevisionBPMCBlueprint Medicines1.0832 of 5 stars$128.40+0.0%$128.25-0.1%+13.2%$8.29B$508.82M-51.98640News CoveragePositive NewsVRNAVerona Pharma PLC American Depositary Share2.2988 of 5 stars$91.20-0.4%$107.36+17.7%+358.8%$7.79B$42.28M-45.6030ROIVRoivant Sciences2.6714 of 5 stars$10.74-2.3%$17.50+62.9%+3.6%$7.47B$29.05M-42.96860ELANElanco Animal Health1.8068 of 5 stars$14.48-1.1%$15.33+5.9%+14.6%$7.27B$4.44B19.579,000Analyst UpgradeAnalyst RevisionRVMDRevolution Medicines4.5503 of 5 stars$36.67-3.2%$68.00+85.4%-15.9%$7.05B$11.58M-9.17250Analyst ForecastLEGNLegend Biotech3.5835 of 5 stars$35.87+0.6%$72.60+102.4%-23.4%$6.55B$627.24M-60.802,609News CoveragePositive NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies VTRS Competitors QGEN Competitors ASND Competitors BBIO Competitors BPMC Competitors VRNA Competitors ROIV Competitors ELAN Competitors RVMD Competitors LEGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALVO) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alvotech Please log in to your account or sign up in order to add this asset to your watchlist. Share Alvotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
